| Literature DB >> 25651156 |
Paulo Michel Pinheiro Ferreira1, Patricia Marçal Da Costa2, Arinice de Menezes Costa2, Daisy Jereissati Barbosa Lima2, Renata Rosado Drumond3, Jurandy do Nascimento Silva3, Diogo Rodrigo de Magalhães Moreira4, Gevânio Bezerra De Oliveira Filho4, Jamile Magalhães Ferreira5, Maria Goretti Rodrigues De Queiroz5, Ana Cristina Lima Leite4, Cláudia Pessoa2.
Abstract
Eleven phthalimide derivatives were evaluated with regards to their antiproliferative activity on tumor and normal cells and possible toxic effects. Cytotoxic analyses were performed against murine tumors (Sarcoma 180 and B-16/F-10 cells) and peripheral blood mononuclear cells (PBMC) using MTT and Alamar Blue assays. Following, the investigation of cytotoxicity was executed by flow cytometry analysis and antitumoral and toxicological potential by in vivo techniques. The molecules 3b, 3c, 4 and 5 revealed in vitro cytotoxicity against Sarcoma 180, B-16/F-10 and PBMC. Since compound 4 was the most effective derivative, it was chosen to detail the mechanism of action after 24, 48 and 72 h exposure (22.5 and 45 µM). Sarcoma 180 cells treated with compound 4 showed membrane disruption, DNA fragmentation and mitochondrial depolarization in a time- and dose-dependent way. Compounds 3c, 4 and 5 (50 mg/kg/day) did not inhibit in vivo tumor growth. Compound 4-treated animals exhibited an increase in total leukocytes, lymphocytes and spleen relative weight, a decreasing in neutrophils and hyperplasia of spleen white pulp. Treated animals presented reversible histological changes. Molecule 4 had in vitro antiproliferative action possibly triggered by apoptosis, reversible toxic effects on kidneys, spleen and livers and exhibited immunostimulant properties that can be explored to attack neoplasic cells.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25651156 DOI: 10.1590/0001-3765201520130345
Source DB: PubMed Journal: An Acad Bras Cienc ISSN: 0001-3765 Impact factor: 1.753